GB1390772A - Oral narcotic composition - Google Patents

Oral narcotic composition

Info

Publication number
GB1390772A
GB1390772A GB1131972A GB1131972A GB1390772A GB 1390772 A GB1390772 A GB 1390772A GB 1131972 A GB1131972 A GB 1131972A GB 1131972 A GB1131972 A GB 1131972A GB 1390772 A GB1390772 A GB 1390772A
Authority
GB
United Kingdom
Prior art keywords
narcotic
salts
composition
orally
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1131972A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENDO LAB
Original Assignee
ENDO LAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ENDO LAB filed Critical ENDO LAB
Publication of GB1390772A publication Critical patent/GB1390772A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1390772 Narcotic compositions ENDO LABORATORIES INC 10 March 1972 [7 May 1971] 11319/72 Heading A5B Pharmaceutical compositions comprise: (a) a compound, having substantial narcotic activity both orally and by injection, selected from oxycodone, hydrocodone, codeine, propoxyphene and pentazocine, and salts thereof and, (b) a narcotic antagonist which is substantially less active orally than by injection selected from: (i) naloxone and its pharmaceutically acceptable salts, (ii) N-cyclopropylmethyl-7, 8-dihydro-14-hydroxynormophinone and its salts and, (iii) 21-cyclopropyl-7#-(1- hydroxy-1-methylethyl)-6, 14-endo-ethano-tetrahydrooripavine and its salts, the weight ratio of (a) to (b) being within certain ranges according to the individual compounds used so that substance (b) does not block the narcotic effect of (a) when the composition is administered orally, but does prevent an acute euphoriant effect by (a) when the composition is injected. Other active substances may also be present, e.g. aspirin, phenacetin, caffeine, antihistamines and antispasmodics.
GB1131972A 1971-05-07 1972-03-10 Oral narcotic composition Expired GB1390772A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14140771A 1971-05-07 1971-05-07

Publications (1)

Publication Number Publication Date
GB1390772A true GB1390772A (en) 1975-04-16

Family

ID=22495561

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1131972A Expired GB1390772A (en) 1971-05-07 1972-03-10 Oral narcotic composition

Country Status (3)

Country Link
DE (1) DE2222039A1 (en)
FR (1) FR2137560B1 (en)
GB (1) GB1390772A (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0900582A1 (en) * 1997-08-21 1999-03-10 Johnson Matthey Public Limited Company Method for removal of residual organic solvents from a crystalline bulk substance and use thereof in manufacturing pharmaceuticals
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
EP1299104A1 (en) * 2000-02-08 2003-04-09 Euro-Celtique, S.A. Tamper-resistant oral opioid agonist formulations
WO2003084520A2 (en) * 2002-04-05 2003-10-16 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
EP1810678A1 (en) * 2006-01-19 2007-07-25 Holger Lars Hermann Use of morphine and naloxone for drug substitution
US8465774B2 (en) 2001-08-06 2013-06-18 Purdue Pharma L.P. Sequestered antagonist formulations
US8518925B2 (en) 2004-06-08 2013-08-27 Euro-Celtique S.A. Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
US8673355B2 (en) 1997-12-22 2014-03-18 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8822487B2 (en) 1997-12-22 2014-09-02 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9101625B2 (en) 2006-08-30 2015-08-11 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US10258235B2 (en) 2005-02-28 2019-04-16 Purdue Pharma L.P. Method and device for the assessment of bowel function

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
WO1993002707A1 (en) * 1991-08-06 1993-02-18 Byk Gulden Lomberg Chemische Fabrik Gmbh New anti-diarrheic agents
FR2681922B1 (en) * 1991-09-30 1993-11-26 Bendix Europe Services Technique FRICTION MEMBER PROVIDED WITH A WEAR INDICATOR DEVICE AND DISC BRAKE EQUIPPED WITH SUCH A MEMBER.
NZ505192A (en) 1997-12-22 2003-05-30 Euro Celtique S A method of preventing abuse of opioid dosage forms , whereby opioid agonist and opioid antagonist are only extractable together
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
SI1414451T1 (en) 2001-08-06 2009-10-31 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
CN1703200B (en) 2002-09-20 2012-02-29 奥尔制药公司 Sequestering subunit and related compositions and methods
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
DK2034975T3 (en) 2006-06-19 2012-07-23 Alpharma Pharmaceuticals Llc Pharmaceutical compositions
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981751A (en) * 1997-08-12 1999-11-09 Johnson Matthey Public Limited Company Method for removal of residual organic solvents and use thereof in manufacturing pharmaceuticals
EP0900582A1 (en) * 1997-08-21 1999-03-10 Johnson Matthey Public Limited Company Method for removal of residual organic solvents from a crystalline bulk substance and use thereof in manufacturing pharmaceuticals
US9205082B2 (en) 1997-12-22 2015-12-08 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8932630B1 (en) 1997-12-22 2015-01-13 Purdue Pharma L.P Opioid agonist/antagonist combinations
US8822487B2 (en) 1997-12-22 2014-09-02 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US8673355B2 (en) 1997-12-22 2014-03-18 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8586088B2 (en) 2000-02-08 2013-11-19 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7682632B2 (en) 2000-02-08 2010-03-23 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US10588865B2 (en) 2000-02-08 2020-03-17 Purdue Pharma L.P. Tamper resistant oral opioid agonist formulations
AP1665A (en) * 2000-02-08 2006-09-22 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations.
US10350173B2 (en) 2000-02-08 2019-07-16 Purdue Pharma L.P. Tamper resistant oral opioid agonist formulations
US9801828B2 (en) 2000-02-08 2017-10-31 Purdue Pharma L.P. Tamper resistant oral opioid agonist formulations
US9456989B2 (en) 2000-02-08 2016-10-04 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
CZ299991B6 (en) * 2000-02-08 2009-01-14 Euro-Celtique S.A. Medicamentous dosage form
US7658939B2 (en) 2000-02-08 2010-02-09 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8357399B2 (en) 2000-02-08 2013-01-22 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7718192B2 (en) * 2000-02-08 2010-05-18 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US9278073B2 (en) 2000-02-08 2016-03-08 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7842309B2 (en) 2000-02-08 2010-11-30 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7842311B2 (en) 2000-02-08 2010-11-30 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
EP1299104A4 (en) * 2000-02-08 2004-04-21 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US8936812B2 (en) 2000-02-08 2015-01-20 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8236351B2 (en) 2000-02-08 2012-08-07 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
EP1299104A1 (en) * 2000-02-08 2003-04-09 Euro-Celtique, S.A. Tamper-resistant oral opioid agonist formulations
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
AU2002316738B2 (en) * 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
WO2003007802A3 (en) * 2001-07-18 2003-11-27 Euro Celtique Sa Pharmaceutical combinations of oxycodone and naloxone
US8465774B2 (en) 2001-08-06 2013-06-18 Purdue Pharma L.P. Sequestered antagonist formulations
US8758825B2 (en) 2001-08-06 2014-06-24 Purdue Pharma L.P. Sequestered antagonist formulations
JP2010180233A (en) * 2002-04-05 2010-08-19 Euro-Celtique Sa Pharmaceutical preparation containing oxycodone and naloxone
EP2425825B1 (en) 2002-04-05 2016-11-16 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US10420762B2 (en) 2002-04-05 2019-09-24 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
CN1646102B (en) * 2002-04-05 2012-08-15 欧洲凯尔蒂克公司 Pharmaceutical preparation containing oxycodone and naloxone
JP4755810B2 (en) * 2002-04-05 2011-08-24 ユーロ−セルティーク エス．エイ． Pharmaceutical formulation containing oxycodone and naloxone
US9655855B2 (en) 2002-04-05 2017-05-23 Purdue Pharma L.P. Matrix for sustained, invariant and independent release of active compounds
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
WO2003084520A2 (en) * 2002-04-05 2003-10-16 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
WO2003084520A3 (en) * 2002-04-05 2004-03-11 Euro Celtique Sa Pharmaceutical preparation containing oxycodone and naloxone
AU2003224040B2 (en) * 2002-04-05 2006-06-22 Mundipharma Pty Limited Pharmaceutical preparation containing oxycodone and naloxone
US9555000B2 (en) 2002-04-05 2017-01-31 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US8846090B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US8846091B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US9907793B2 (en) 2002-04-05 2018-03-06 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US8518925B2 (en) 2004-06-08 2013-08-27 Euro-Celtique S.A. Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
US10258235B2 (en) 2005-02-28 2019-04-16 Purdue Pharma L.P. Method and device for the assessment of bowel function
EA014539B1 (en) * 2006-01-19 2010-12-30 Фенукс Аг Use of a combination of morphine and at least one opiate antagonists for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts
US10507205B2 (en) 2006-01-19 2019-12-17 Purdue Pharmaceutical Products L.P. Methods of treating opiate dependency and preventing non-oral opiate abuse among opiate addicts
WO2007082935A1 (en) * 2006-01-19 2007-07-26 Phoenux Ag Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts
EP1810678A1 (en) * 2006-01-19 2007-07-25 Holger Lars Hermann Use of morphine and naloxone for drug substitution
US9101625B2 (en) 2006-08-30 2015-08-11 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9861628B2 (en) 2006-08-30 2018-01-09 Rhodes Pharmaceuticals L.P. Buprenorphine-wafer for drug substitution therapy
US9763931B2 (en) 2006-08-30 2017-09-19 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9370512B2 (en) 2006-08-30 2016-06-21 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9820983B2 (en) 2009-03-10 2017-11-21 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation

Also Published As

Publication number Publication date
FR2137560B1 (en) 1975-10-31
FR2137560A1 (en) 1972-12-29
DE2222039A1 (en) 1972-11-23

Similar Documents

Publication Publication Date Title
GB1390772A (en) Oral narcotic composition
GB1517480A (en) Opiate analgesic formulation with a low potential for abuse
FI905718A (en) TRANSDERMALT MEDEL.
NZ177159A (en) Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions
IE45439L (en) Penicillanic acid derivatives
GB841697A (en) Analgesic compositions
GB1321509A (en) Azepine derivatives
IE782422L (en) Dispersions of clavulanic acid particles
GB1487334A (en) Pharmaceutical preparations comprising lisuride and/or physiologically tolerable salts thereof
GB1183403A (en) Antitussive Medicament with Prolonged Effect
WO1991018606A3 (en) Orally active nonaddicting analgesics
GB1174051A (en) Aminophenol Derivatives and Analgesic and Antipyretic Compositions
ATE81775T1 (en) PHARMACEUTICAL COMPOSITIONS.
GB1463505A (en) Pharmaceutical compositions
GB1442159A (en) Pharmaceutical compositions containing paracetamol
GB1349138A (en) Quinazoline derivative
ES8306593A1 (en) Compositions for topical use containing Ergot or Vinca Rosea alkaloids for treatment of hyperseborrhoea, and their preparation.
GB1507643A (en) 4-(5-nitro-2-furyl)quinaldinic acid n-oxide and its use in the treatment of bovine mastitis
US3800041A (en) Analgesic compositions and methods
US3795736A (en) 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1) benzopyrano(3,4-d)pyridine as an analgesic agent
GB1302353A (en)
GB1254057A (en) Improvements in or relating to therapeutical composition containing vincamine
GB1375806A (en)
RU2083202C1 (en) Analgetic preparation
GB1261454A (en) Improved analgesic systems and compositions

Legal Events

Date Code Title Description
PS Patent sealed
PLNP Patent lapsed through nonpayment of renewal fees
49R Reference inserted (sect. 9/1949)
SP Amendment (slips) printed